AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03861936 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: OnabotulinumtoxinA
Description: OnabotulinumtoxinA (botulinum toxin Type A;BOTOX®) administered intramuscularly to the bilateral masseter muscles on Day 1.
Study NCT03861936 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: Normal saline (placebo) administered intramuscularly to the bilateral masseter muscles on Day 1.
Study NCT02833922 — intervention group
Intervention type: BEHAVIORAL
Intervention: Women using Dot to avoid pregnancy
Description: Women who have chosen to use Dot to prevent pregnancy will be followed for 13 cycles to assess perfect and typical use of the Dynamic Optimal Timing method.
Study NCT01795885 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 16 and Pregnant
Description: Participants in this arm will be asked to watch an approximately 45-minute commercial-free episode of the MTV television show 16 and Pregnant once a week for 4 weeks. They will receive an email that contains a link to watch an episode of the show on the internet. The site where the videos are hosted is password protected and they are given the password in the same email. They can watch the video at any time, and can come back to it later if they need to stop watching it. The participants are asked to all watch the same episode each week. Four episodes were selected for the intervention from the first three seasons of the show.
Study NCT00702364 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: atomoxetine
Study NCT00702364 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study NCT01710384 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: betamethasone
Study NCT01312038 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simethicone
Description: single 125 mg chewable tablet
Study NCT01312038 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: chewable calcium tablet
Study NCT03597230 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dye
Description: Cover key details of the intervention. Must be sufficiently detailed to distinguish between arms of a study and/or among similar interventions At the beginning of the surgical procedure, 1 ml of blue patent will be injected in the normal remaining part of the pancreas. The diffusion of the dye among all lymph node areas will be noticed by the surgeon.
Study NCT03615677 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LXI-15028 50mg
Description: The investigational products are administrated orally, once in the morning every day, and each dose includes 2 tablets of investigational products (LXI-15028 50mg active agent + Esomeprazole 40mg matching placebo . If the investigational product is not taken in the morning, subjects can take it before 6:00 p.m. on the same day. The duration of treatment is 4 or 8 weeks.
Study NCT03615677 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Esomeprazole 40mg
Description: The investigational products are administrated orally, once in the morning every day, and each dose includes 2 tablets of investigational products ( LXI-15028 50mg matching placebo + Esomeprazole 40mg active agent ). If the investigational product is not taken in the morning, subjects can take it before 6:00 p.m. on the same day. The duration of treatment is 4 or 8 weeks.
Study NCT01349465 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: No treatment
Description: No treatment was given to patients during this study as this is a follow-up study of previous Phase IIb or Phase III in which they received a TMC435-containing regimen.
Study NCT03099642 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: ultrasound-assisted lumbar puncture
Description: The ultrasound probe type will be selected by the treating pediatric emergency physician who has been trained according to standards outlined below. They will first identify the conus medullaris and make a horizontal marking with a sterile pen on the patient's back. Using a transverse view, they will then identify the midline of the patient's spine (using adjacent spinous processes) and will make 2 vertical skin markings on either side of the probe. Next, they will orient the probe in a longitudinal view to identify the desired vertebral interspace and will make 2 horizontal skin markings on either side of the probe at this level. Finally the 4 lines will be joined together at an intersection point, which will be the predetermined site for puncture attempt.
Study NCT02332499 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anlotinib
Description: Anlotinib p.o. qd
Study NCT02332499 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo p.o. qd
Study NCT01612182 — intervention group
Intervention type: OTHER
Intervention: renal replacement therapy
Description: renal replacement therapy : hemodialysis and/or CRRT(continuous renal replacement therapy )
Study NCT00309465 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lantus
Description: Patients in Group 1 will administer 80% of their usual insulin glargine dose.
Study NCT00309465 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Insulin
Description: Group 2 patients will contact their own diabetes care physician and follow those recommendations for the dose
Study NCT00309465 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lantus
Description: Group 3 patients will take 50%, 80%, or 100% of their usual insulin glargine dose. Which of those three percentages will be determined by the midpoint of the patient's usual self-reported fasting blood sugar (FBS) range and whether the patients is also taking a rapid-acting insulin.
Study NCT03270189 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: prism glasses
Description: orthoptic treatment by wearing prisms when writing
Study NCT02902354 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Nifedipine for tocolysis
Description: observational
Study NCT00383084 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle physical activity (LPA)
Description: Bi-weekly, 60-minute group sessions spread over 12 weeks. Participants will receive education on how to increase their daily physical activity, goal setting, problem solving strategies to overcome barriers to being more physically active, and finding new ways to integrate short bouts of LPA into their daily lives.
Study NCT00383084 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Fibromyalgia education
Description: Participants will meet monthly for 1.5 to 2 hours for a total of 3 months. The sessions will be divided into three components: (1) education, (2) question and answer, and (3) social support.
Study NCT01877187 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Lipiodol
Description: Lipiodol is used as a carrier for chemotherapy agents and also as an occlusion agent. In TACE procedures, Lipiodol is mixed with the chemotherapy agent(s) and delivered to the tumor via the hepatic artery, causing necrosis of the targeted tumor(s).
Study NCT01599520 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Spanish-Language Self-Administered Training Plus Usual Care (SL-SAT)
Description: Patients will receive usual care. In addition, a Spanish-speaking intervention associate will spend an extra 10 minutes on the day usual care is initiated reviewing the self-administered training materials in Spanish titled Cómo tratar el estrés durante la quimioterapia. Materials consist of an 18-minute DVD (also available as a videocassette (VC)), a 28-minute CD (also available as an audiocassette (AC)), a 16-page booklet, and a workbook to record practice and use of stress management techniques. Participants are instructed to first view the DVD/VC and then follow directions in the booklet and on the CD/AC about training, practice, and use of stress management techniques.
Study NCT01599520 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care Only
Description: Patients will be given the Spanish-language version of Chemotherapy and You: Support for People with Cancer (La quimioterapia y usted: Apoyo para las personas con cancer) published by NCI. The intervention associate will review how it provides answers to common questions about chemotherapy, describes common side effects and their management, and identifies ways to obtain additional information. Patients will also be provided with a list of local support groups for cancer patients and informed that a social worker is available to meet with them without charge to discuss personal concerns or practical problems. At the first infusion, oncology nurses will provide all patients with standard education about the chemotherapy agents and anti-emetic agents to be administered, possible adverse reactions to these agents, and recommended precautions for avoiding illness and maintaining health.
Study NCT00330876 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pitavastatin
Study NCT05088642 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hetrombopag Olamine Tablet
Description: Hetrombopag Olamine Tablet
Study NCT02164929 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TAP block
Study NCT02164929 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Epidural
Study NCT02164929 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Paravertebral block
Study NCT02164929 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetaminophen 1g IV
Study NCT02164929 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone 4mg
Study NCT02164929 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam up to 2mg
Study NCT02164929 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol 1-2.5 mg/kg
Study NCT02164929 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sevoflurane to keep a bispectral index of between 40-60
Study NCT02164929 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Local infiltration with 10 mL of plain ropivacaine 0.25%
Study NCT02164929 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine
Description: 1.5% lidocaine
Study NCT02164929 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epinephrine
Description: 1:200,000 epinephrine
Study NCT02164929 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydromorphone
Description: 400-800 mcg Hydromorphone will be given preoperatively
Study NCT02969187 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exparel
Description: 6 trocars are placed to perform LRYGB or LSG: two 12 mm trocars and four 5 mm trocars. Exparel will be injected at port sites.
Study NCT02969187 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacain
Description: 6 trocars are placed to perform LRYGB or LSG: two 12 mm trocars and four 5 mm trocars. Bupivacain will be injected at port sites.
Study NCT02969187 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacain
Description: 6 trocars are placed to perform LRYGB or LSG: two 12 mm trocars and four 5 mm trocars. Bupivacain will be injected at port sites.
Study NCT02969187 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Saline
Study NCT02969187 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saline
Study NCT04717518 — intervention group
Intervention type: OTHER
Intervention: Measurement of Pain
Description: Patients will fill out a brief survey concerning the current visit to the ED.
Study NCT03668600 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rapastinel
Description: Rapastinel 450 mg (prefilled syringe, weekly or biweekly or up to 4 weeks at the investigator's discretion intravenous IV administration)
Study NCT02793440 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: cortivazol treatment
Study NCT02793440 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: lumbar traction
Study NCT02793440 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: lumbar traction
Study NCT01512836 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Case Management
Description: Patients, who are randomized to the intervention group, will receive case management from a trained and experienced nurse. The case manager will carry out following tasks:~* Formulation and implementation of care plans together with the patient~* Monitoring of individual status and care plan effectuation~* Overall coordination between health care providers~* Support to the patient and their caregivers during times of transition related to health status and environmental changes (e.g. hospital to home)~* Regular telephone consultations and home visits~* Promote disease-self management through coaching
Study NCT01438489 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anifrolumab 300 mg
Description: Participants will receive 300 milligram (mg) anifrolumab as an intravenous infusion every 4 weeks for 48 weeks.
Study NCT01438489 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anifrolumab 1000 mg
Description: Participants will receive 1000 mg anifrolumab as an intravenous infusion every 4 weeks for 48 weeks.
Study NCT01438489 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive placebo matched to anifrolumab intravenous (IV) infusion every 4 weeks for 48 weeks.
Study NCT05699889 — intervention group
Intervention type: OTHER
Intervention: Data collection
Description: acute kidney injury and tubular dysfunction
Study NCT03437382 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Quirem Medical Holmium-166 radioembolization microspheres
Description: radioembolisation as adjuvant treatment to RFA
Study NCT01147289 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dextralgen
Description: Dexalgen® will be administered at a dose equivalent to dexamethasone 1.5 mg, dipyrone 500 mg, and hydroxocobalamin 5 mg (one ampoule for each type) a day at a single intramuscular dose. Both drugs will be administered for 3 days, at least.
Study NCT01147289 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Meloxicam
Description: Meloxicam (Movatec®, Boehringer Ingelheim) will be administered as 15 mg (one ampoule) a day at a single intramuscular dose. Both drugs will be administered for 3 days, at least.
Study NCT02887664 — intervention group
Intervention type: PROCEDURE
Intervention: Blood test
Description: Blood will be drawn from mother's vein and from the cord to test for n-6:n-3 ratio and inflammatory markers: CRP, IL-6, TPO and TNF-alpha markers
Study NCT00865059 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gabapentin 800 mg Tablets, single dose
Description: A: Experimental Subjects received Purepac formulated products under non-fasting conditions
Study NCT00865059 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NEURONTIN® 800 mg Tablets, single dose
Description: B: Active comparator Subjects received Parke-Davis formulated products under non-fasting conditions
Study NCT02446314 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Formulation containing inert artificially colored maltodextrin, once daily, in a 2-hard capsule regimen
Study NCT02446314 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Wild Blueberry Powder - 450mg
Description: Formulation containing 225 mg wild blueberry powder + 22.5 mg L-Cysteine @ 2.5 mg L-Glutathione 250 mg placebo powder, once daily, in a 2-hard capsule regimen
Study NCT02446314 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Wild Blueberry Powder - 900 mg
Description: Formulation containing 450 mg wild blueberry powder = 45 mg L-Cysteine + 5 mg L-Glutathione once daily, in a 2-hard capsule regimen
Study NCT02446314 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Wild Blueberry extract 100mg
Description: Formulation containing 100 mg wild blueberry powder + 10 mg L-Cysteine + 1 mg L-Glutathione + 389 mg of placebo, once daily, in a 2-hard capsule regimen
Study NCT02036242 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sole local anesthetic
Description: 0.125% ropivacaine 10-15 ml every 1h during labor delivery
Study NCT02036242 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sufentanil (Opioid plus local anesthetic)
Description: Sufentanil combined with 0.125% ropivacaine, 10-15 ml every 1h during labor delivery
Study NCT02036242 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine
Study NCT02036242 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine
Study NCT00984971 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir
Description: Topical gel applied rectally
Study NCT00984971 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: HEC Placebo
Description: Placebo gel applied rectally
Study NCT00984971 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Open label tenofovir tablet
Description: All participants will undergo an open label tenofovir tablet single dose administration (i.e. Tenofovir Disoproxil Fumarate 300 mg, aka Viread®)
Study NCT03506321 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: chromoendoscopy, high definition white light and narrow band imaging
Description: Chromoendoscopy, high definition white light and narrow band imaging are compared for predicting submucosal invasion within laterally spreading lesions in the colon and determining the presence of residual or recurrent adenoma at the post endoscopic resection scar
Study NCT03382977 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VBI-1901
Description: The vaccine is formulated with GM-CSF adjuvant and administered intradermally (ID) or with AS01B adjuvant and administered intramuscularly (IM) to patients with recurrent GBM.
Study NCT03382977 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carmustine
Description: Treatment with carmustine intravenously at a dose of 150 mg/m² on Day 1 and every 6 weeks until the earlier of disease progression or intolerable toxicity.
Study NCT03382977 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lomustine
Description: Treatment with lomustine given orally at a dose of 110 mg/m² (up to a maximum dose of 200 mg) on Day 1 and every 6 weeks until the earlier of disease progression or intolerable toxicity.
Study NCT05526690 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: 1000 mg dose of immediate-release metformin
Study NCT05526690 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: 1000 mg dose of immediate-release metformin
Study NCT05526690 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CIN-107
Description: 10 mg dose of CIN-107
Study NCT02439996 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IVIG (1g/kg,once)
Description: Group C patients received IVIG 1g/kg per day once. The IVIG was started on the fifth to tenth day of illness. In combination with IVIG, the patients were administered aspirin at a dose of 30 mg/kg per day; this dose was reduced to 3-5 mg/kg per day after the fever disappeared for 3 days and the CRP value was ≤8mg/L. Patients who were admitted before the fourth day of illness were treated only with aspirin. Each immunoglobulin was administered at a dose of 1 g/kg for 10h.~Patients who did not respond to initial IVIG therapy were given a second dose of IVIG 24-36 hours after the initial dose at 2g/kg. Patients who did not respond to second dose IVIG were given methylprednisolone 10mg/kg for 3 days or infliximab 5mg/kg once.
Study NCT02439996 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IVIG (1g/kg,twice)
Description: Group B patients received IVIG 1g/kg for 2 days continuously. The IVIG was started on the fifth to tenth day of illness. In combination with IVIG, the patients were administered aspirin at a dose of 30 mg/kg per day; this dose was reduced to 3-5 mg/kg per day after the fever disappeared for 3 days and the CRP value was ≤8mg/L. Patients who were admitted before the fourth day of illness were treated only with aspirin. Each immunoglobulin was administered at a dose of 1 g/kg for 10h.~Patients who did not respond to initial IVIG therapy were given a second dose of IVIG 24-36 hours after the initial dose at 2g/kg. Patients who did not respond to second dose IVIG were given methylprednisolone 10mg/kg for 3 days or infliximab 5mg/kg once.
Study NCT02439996 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IVIG (2g/kg.once)
Description: Group A patients received IVIG 2g/kg per day once. The IVIG was started on the fifth to tenth day of illness. In combination with IVIG, the patients were administered aspirin at a dose of 30 mg/kg per day; this dose was reduced to 3-5 mg/kg per day after the fever disappeared for 3 days and the CRP value was ≤8mg/L. Patients who were admitted before the fourth day of illness were treated only with aspirin. Each immunoglobulin was administered at a dose of 1 g/kg for 10h.~Patients who did not respond to initial IVIG therapy were given a second dose of IVIG 24-36 hours after the initial dose at 2g/kg. Patients who did not respond to second dose IVIG were given methylprednisolone 10mg/kg for 3 days or infliximab 5mg/kg once.
Study NCT01105676 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: skin biopsy
Description: Two skin biopsies will be taken one time
Study NCT03083704 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Andexanet alfa (Gen 1 Process 2)
Description: factor Xa inhibitor antidote
Study NCT03083704 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apixaban 5 MG
Description: factor Xa inhibitor
Study NCT03083704 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban 20 MG
Description: factor Xa inhibitor